Treatment of an established graft-versus-host reaction in AKR mice by adoptive immunotherapy.
A model system in AKR mice for the induction and cure of a clinically evident graft-versus-host disease is reported. Graft-versus-host disease is inititated by i.p. injections of ecyclophosphamide (250 mg/kg body weitht ) into female AKR mice, on Day 0. This is followed by i.v. injections of 45 x 10-6 normal spleen cells (NSC) from male C57BL/6J mice. Median survival time for these mice is 33.4 plus or minus 4.5 days. Following the administration of C57BL/6J NSC, AKR mice were rescued from graft-versus-host disease by the following treatment protocol: (a) Day 6, 35 x 10-6 DBA/2 NSC given i.v.; (b) Day 10, cyclophosphamide i.p. (150 mg/kg body weight); (c) Days 11 and 26, 35 x 10-6 AKR NSC given i.v. These experiments demonstrate that graft-versus-host reaction can be elminiated by coupling a graft-versus-host reaction with a graft-versus-graft reaction and restoring the host by immunocompetent syngeneic cells.
D000818:Animals; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006087:Graft vs Host Reaction / Q000209:etiology / Q000628:therapy*; D006649:Histocompatibility Antigens; D007112:Immunity, Maternally-Acquired; D007116:Immunization, Passive; D007167:Immunotherapy; D008297:Male; D051379:Mice; D008806:Mice, Inbred AKR; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D008954:Models, Biological; D013154:Spleen / Q000276:immunology / Q000637:transplantation; D014183:Transplantation, Heterologous; D014184:Transplantation, Homologous
D006649:Histocompatibility Antigens; D003520:Cyclophosphamide